DIMA

DIMA:

Leading product AF-29 is in late preclinical stage of development. Superior IL-1 signaling inhibition efficacy and prolonged PK were confirmed in rodent models. IND application is expected in Q2/2026

AF-29
  • Manufacturing process development completed; High production yield in stable CHO expression system
  • Non-GLP monkey toxicity studies completed; no sign of toxicity or abnormal blood chemistry parameter observed  in Cyno monkey at 150 mg/kg
  • Dual targeting inflammatory receptor and cytokine
  • Enhanced efficacy by synergistic IL-1 signaling blockade
  • Decrease side effects by minimizing systemic IL-1 signaling inhibition
  • More efficacious than approved IL-1 neutralizing drugs in multiple murine models
  • Broad inflammatory disease indications: inflammatory disease (such as severe and recurring goat and osteoarthritis), cancers and IL-1 relevant rare disease
Scroll to Top